Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
19 nov. 2020 16h11 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff...
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays
26 oct. 2020 06h30 HE
|
Interpace Biosciences, Inc.
Study Demonstrates Superior Performance of ThyGeNEXT® and ThyraMIR® vs. Other Molecular Tests PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
Interpace Biosciences Announces Second Quarter 2020 Financial and Business Results
20 oct. 2020 08h00 HE
|
Interpace Biosciences, Inc.
Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million Publication of Seminal Clinical Validation Study Related to Thyroid Products ...
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
14 oct. 2020 06h30 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has...
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
20 août 2020 08h30 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on August 18, 2020 received notice from the Listing Qualifications Staff...
Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays
21 juil. 2020 06h05 HE
|
Interpace Biosciences, Inc.
Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
Interpace Biosciences Announces First Quarter 2020 Financial and Business Results
25 juin 2020 16h59 HE
|
Interpace Biosciences, Inc.
First Quarter Net Revenue Improved Over 53% to $9.2 Million Launching COVID-19 Serology Testing Continues to Integrate Service Offerings and Streamline Costs Conference Call and Webcast Thursday...
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020
24 juin 2020 16h20 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m....
Interpace Biosciences Announces Contract with Lab Benefits Management Firm
27 avr. 2020 06h55 HE
|
Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, April 27, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace...
Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results
22 avr. 2020 16h05 HE
|
Interpace Biosciences, Inc.
Acquired Biopharma Business of Cancer Genetics in Second Half of 2019 Through Q1-2020 Raised $47 million from Two Top Private Equity FirmsProvides First Quarter 2020 Range of Revenues Expects to...